With over 26.53 million AlloVir Inc (ALVR) shares trading Friday and a closing price of $0.77 on the day, the dollar volume was approximately $20.43 million. The shares have shown a negative half year performance of -76.66% and its price on 12/22/23 lost nearly -67.15%. Currently, there are 93.09M common shares owned by the public and among those 56.89M shares have been available to trade.
Insiders at the company have transacted a total of 46 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 14 of these insider trades were purchases, accounting for 4,005,370 shares. Insider sales of the common stock occurred on 32 occasions, with total insider shares sold totaling 122,469 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Shares of AlloVir Inc (NASDAQ: ALVR) opened at $0.7615, down -$1.57 from a prior closing price of $2.33. The company’s stock has a 5-day price change of -67.70% and -67.43% over the past three months. ALVR shares are trading -85.08% year to date (YTD), with the 12-month market performance down to -86.50% lower. It has a 12-month low price of $1.31 and touched a high of $7.24 over the same period. ALVR has an average intraday trading volume of 813.94K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -63.45%, -56.83%, and -75.44% respectively.
Institutional ownership of AlloVir Inc (NASDAQ: ALVR) shares accounts for 49.12% of the company’s 93.09M shares outstanding.
It has a market capitalization of $87.30M and a beta (3y monthly) value of 1.09. The earnings-per-share (ttm) stands at -$1.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.90% over the week and 9.31% over the month.
Analysts forecast that AlloVir Inc (ALVR) will achieve an EPS of -$0.4 for the current quarter, -$0.18 for the next quarter and -$0.79 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.44 while analysts give the company a high EPS estimate of -$0.34. Comparatively, EPS for the current quarter was -$0.37 a year ago. Earnings per share for the fiscal year are expected to increase by 20.67%, and 71.67% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate AlloVir Inc (ALVR) as a “Hold” at a consensus score of 3.60. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 3 of the 5 advise that investors “hold,” and 1 rated it as a “Sell.”
